Evidence map›Paper›PMID 30006374›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with

S Moses Dennison, Matthew Reichartz, Kelly E Seaton, Sheetij Dutta, Ulrike Wille-Reece, Adrian V S Hill, Katie J Ewer, Wes Rountree, Marcella Sarzotti-Kelsoe, Daniel A Ozaki and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  3. IgA and IgG1 Specific to Vi Polysaccharide ofFrontiers in immunology · 2019
    Trial
  4. High-Throughput BLI for One-Step Anti-International journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Malaria vaccines: a new era of prevention and control.Nature reviews. Microbiology · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

S Moses DennisonDuke Human Vaccine Institute, Duke University, Durham, NC 27710; georgia.tomaras@duke.edu moses.sekaran@duke.edu.ORCID 0000-0003-1198-9179
Matthew ReichartzDuke Human Vaccine Institute, Duke University, Durham, NC 27710.
Kelly E SeatonDuke Human Vaccine Institute, Duke University, Durham, NC 27710.ORCID 0000-0002-2009-3270
Sheetij DuttaWalter Reed Army Institute of Research, Silver Spring, MD 20910.
Ulrike Wille-ReecePATH's Malaria Vaccine Initiative, Washington, DC 20001.
Adrian V S HillThe Jenner Institute, Oxford OX3 7DQ, United Kingdom.ORCID 0000-0003-0900-9629
Katie J EwerThe Jenner Institute, Oxford OX3 7DQ, United Kingdom.ORCID 0000-0001-9827-9836
Wes RountreeDuke Human Vaccine Institute, Duke University, Durham, NC 27710.
Marcella Sarzotti-KelsoeDuke Human Vaccine Institute, Duke University, Durham, NC 27710.
Daniel A OzakiDuke Human Vaccine Institute, Duke University, Durham, NC 27710.
S Munir AlamDuke Human Vaccine Institute, Duke University, Durham, NC 27710.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, NC 27710; georgia.tomaras@duke.edu moses.sekaran@duke.edu.ORCID 0000-0001-8076-1931
Duke University · USJenner Institute · GBU.S. President's Malaria Initiative · USWalter Reed Army Institute of Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ab avidity is a measure of the overall strength of Ab-Ag interactions and hence is important for understanding the functional efficiency of Abs. In vaccine evaluations, Ab avidity measurements can provide insights into immune correlates of protection and generate hypotheses regarding mechanisms of protection to improve vaccine design to achieve higher levels of efficacy. The commonly used Ab avidity assays require the use of chaotropic reagents to measure avidity index. In this study, using real-time detection of Ab-Ag binding by biolayer interferometry (BLI) technique, we have developed a qualified assay for measuring avidity of vaccine-induced Abs specific for

Indexed as

Antibodies, ProtozoanAntibody AffinityAntigens, ProtozoanHumansInterferometryMalaria, FalciparumMalaria VaccinesPlasmodium falciparumAntibodies, ProtozoanAntigens, ProtozoanMalaria Vaccines

Identifiers

PMID30006374
PMCPMC6077849
OpenAlexW2884623540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.